Efficacy and safety of cotadutide, a dual glucagon‐like peptide‐1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and safety of cotadutide, a dual glucagon‐like peptide‐1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease
Authors
Keywords
-
Journal
DIABETES OBESITY & METABOLISM
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2022-04-11
DOI
10.1111/dom.14712
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial
- (2021) Frederik Persson et al. DIABETES CARE
- Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study
- (2021) Rajaa Nahra et al. DIABETES CARE
- Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease
- (2020) Johannes F.E. Mann et al. Clinical Journal of the American Society of Nephrology
- NAFLD as a driver of chronic kidney disease
- (2020) Christopher D. Byrne et al. JOURNAL OF HEPATOLOGY
- GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists
- (2020) José Luis Górriz et al. Journal of Clinical Medicine
- 354-OR: Cotadutide (medi0382), a Dual Receptor Agonist with Glucagon-Like Peptide-1 and Glucagon Activity, Modulates Hepatic Glycogen and Fat Content
- (2020) DARREN ROBERTSON et al. DIABETES
- GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms
- (2020) Daiji Kawanami et al. Frontiers in Pharmacology
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art
- (2020) Michael A. Nauck et al. Molecular Metabolism
- Renal Outcomes Associated with the Use of Non-Insulin Antidiabetic Pharmacotherapy: A Review of Current Evidence and Recommendations
- (2020) Mohamed Hassan Elnaem et al. International Journal of General Medicine
- MAFLD and risk of CKD
- (2020) Dan-Qin Sun et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- The single-cell transcriptomic landscape of early human diabetic nephropathy
- (2019) Parker C. Wilson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Efficacy, safety, and mechanistic insights of cotadutide a dual receptor glucagon-like peptide-1 and glucagon agonist
- (2019) Victoria E R Parker et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Impact of Cardio-Renal-Metabolic Comorbidities on Cardiovascular Outcomes and Mortality in Type 2 Diabetes Mellitus
- (2019) David Z.I. Cherney et al. AMERICAN JOURNAL OF NEPHROLOGY
- MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study
- (2018) Philip Ambery et al. LANCET
- Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables
- (2018) Emma Ahlqvist et al. Lancet Diabetes & Endocrinology
- Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETOLOGIA
- Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
- (2017) Christopher Sorli et al. Lancet Diabetes & Endocrinology
- Fatty Liver and Chronic Kidney Disease: Novel Mechanistic Insights and Therapeutic Opportunities
- (2016) Giovanni Musso et al. DIABETES CARE
- Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men
- (2016) M. H. A. Muskiet et al. DIABETES OBESITY & METABOLISM
- Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates
- (2016) S. J. Henderson et al. DIABETES OBESITY & METABOLISM
- Vasodilator Effect of Glucagon: Receptorial Crosstalk Among Glucagon, GLP-1, and Receptor for Glucagon and GLP-1
- (2016) E. Sélley et al. HORMONE AND METABOLIC RESEARCH
- Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
- (2016) Matthew J. Armstrong et al. JOURNAL OF HEPATOLOGY
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diabetic Kidney Disease: A Report From an ADA Consensus Conference
- (2014) Katherine R. Tuttle et al. DIABETES CARE
- Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis
- (2014) Giovanni Musso et al. PLOS MEDICINE
- Epidemiology of Diabetic Kidney Disease
- (2013) Anne T. Reutens MEDICAL CLINICS OF NORTH AMERICA
- Glucagon Effects on Ischemic Vasodilatation in the Isolated Rat Heart
- (2010) Mirko Rosic et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started